Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma

Table 1 Telomerase activity of tumor and normal pancreas

	Cases	Telomerase activity	hTERTmRNA
Tumor	24	21a	20b
Normal	24	3	3

^aP < 0.01 (FI = 28.82);

^bP < 0.01 (FI = 25.42).

Table 2 The relationship between telomerase activity and biological behavior of human pancreatic carcinoma

Biological behavior	Telomerase activity
	–	+	AverageA (+)
Age	63.15 ± 0.45	62.50 ± 0.31	1.21 ± 0.11
Sex
Male	1	12	1.22 ± 0.13
Female	2	9	1.15 ± 0.44
Pathologic type
Cystadenocarcinoma	1	1	1.19
Duct cell adenocystoma	2	19	1.13 ± 0.39
Mucinous adenocystoma		1	1.22
Histologic differentiation
Well-diff.	3	3	0.66 ± 0.33a
Mod-diff.		10	1.10 ± 0.16
Poorly-diff.		8	1.46 ± 0.12
Invasion stage
Non-invasive	1	3	0.86 ± 0.31
Invasive	2	18	1.20 ± 0.35
Lymphnode metastasis
Absent	1	6	0.88 ± 0.31b
Present	2	15	1.31 ± 0.24
TNM stage
I	1	1	1.19
II		5	0.81 ± 0.35c
III	2	10	1.28 ± 0.24
IV		5	1.34 ± 0.12

^aP < 0.01 (F = 26.06);

^bP < 0.01 (t = 3.22);

^cP < 0.01 (F = 9.31).

Table 3 The relationship between telomerase activity and telomerase subunit

Telomerase activity	hTERTa		HTRb		TP1c
	+	-	+	-	+	-
Tumor
+	18	3	19	2	20	2
-	2	1	1	2	2	0
Normal
+	1	2	3	0	3	0
-	1	20	18	3	19	2

^aP > 0.05 (χ² = 0.5);

^bP<0.01 (χ² = 13.76);

^cP < 0.01(χ² = 15.70).

Table 4 The viability of PS-ODNs treated P3 cells (%, ^-x±s)

PS-ODN	C1(3.16) V(%,-x±s)	C2(10) V(%,-x±s)	C3(31.6) V(%,-x±s)	C4(100) V(%,-x±s)
PS-ODN1	92.16 ± 4.2	80.39 ± 5.9	58.11 ± 3.4	33.34 ± 4.6
PS-ODN2	93.40 ± 2.6	84.22 ± 3.6	74.10 ± 3.8	27.35 ± 2.4
PS-ODN3	91.74 ± 4.1	88.75 ± 7.1	86.38 ± 6.7	81.37 ± 5.3
PS-ODN4	94.23 ± 3.3	92.36 ± 5.2	93.72 ± 4.9	91.54 ± 4.4

a.C is the concentration (unit). A is absorbance at 540 μm. V (%) is survival rate. V = A_{CONTRAL GROUP}*100%.

Table 5 The viability of normal fibroblasts treated with PS-ODNs (%,^-x±s)

PS-ODN	C1(3.16) V(%,-x±s)	C2(10) V(%,-x±s)	C3(31.6) V(%,-x±s)	C4(100) V(%,-x±s)
PS-ODN1	104.16 ± 6.4	100.48 ± 3.9	107.20 ± 8.4	103.04 ± 5.7
PS-ODN2	100.80 ± 5.4	97.12 ± 6.7	99.52 ± 7.0	106.72 ± 6.4
PS-ODN3	94.72 ± 4.7	90.56 ± 6.1	92.80 ± 6.8	95.36 ± 3.5
PS-ODN4	100.16 ± 5.6	104.48 ± 5.3	99.04 ± 7.6	106.40 ± 9.2

a.C is the concentration (unit). A is absorbance at 540 μm. V (%) is survival rate. V = A_{CONTRAL GROUP}*100%.

Table 6 Telomerase assay of PS-ODN treated P3 cells (^-x±s)

PS-ODN	C0(0) B(-x±s)	C1(3.16) B(-x±s)	C2(10) B(-x±s)	C3(31.6) B(-x±s)	C4(100) B(-x±s)
PS-ODN1	2.25 ± 0.56	1.53 ± 0.23	1.20 ± 0.15	0.97 ± 0.12	0.65 ± 0.47
PS-ODN2	2.25 ± 0.56	1.66 ± 0.46	1.40 ± 0.44	0.69 ± 0.29	0.49 ± 0.32
PS-ODN3	2.25 ± 0.56	2.28 ± 0.32	2.32 ± 0.37	2.26 ± 0.31	2.19 ± 0.26
PS-ODN4	2.25 ± 0.56	2.16 ± 0.35	2.24 ± 0.50	2.27 ± 0.43	2.13 ± 0.38

a.C0 (0 μmol/L) is the control group. B is telomerase activity.